Profile
Dean A.
Falb worked as Vice President-Research & Development at Stryker Corp.
from 2005 to 2012.
He also worked as Senior Vice President-Research & Development at Praecis Pharmaceuticals, Inc. and as Chief Scientific Officer at LogicBio Therapeutics, Inc. In 2013, he became the Chief Technology Officer at Synlogic, Inc. Dr. Falb holds a doctorate degree from Harvard University and an undergraduate degree from Purdue University.
Former positions of Dean A. Falb
Companies | Position | End |
---|---|---|
SYNLOGIC, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
STRYKER CORPORATION | Chief Tech/Sci/R&D Officer | 01/01/2012 |
LOGICBIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | - |
Training of Dean A. Falb
Harvard University | Doctorate Degree |
Purdue University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
SYNLOGIC, INC. | Health Technology |
STRYKER CORPORATION | Health Technology |
Private companies | 2 |
---|---|
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Health Technology |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Dean A. Falb